uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Almqvist, Ylva
Publications (2 of 2) Show all publications
Steffen, A.-C., Almqvist, Y., Chyan, M.-K., Lundqvist, H., Tolmachev, V., Wilbur, D. S. & Carlsson, J. (2007). Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. Oncology Reports, 17(5), 1141-1147
Open this publication in new window or tab >>Biodistribution of 211At labeled HER-2 binding affibody molecules in mice
Show others...
2007 (English)In: Oncology Reports, ISSN 1021-335X, E-ISSN 1791-2431, Vol. 17, no 5, p. 1141-1147Article in journal (Refereed) Published
Abstract [en]

The size of affibody molecules makes them suitable as targeting agents for targeted radiotherapy with the alpha-emitter 211At, since their biokinetic properties match the short physical half-live of 211At. In this study, the potential for this approach was investigated in vivo. Two different HER-2 binding affibody molecules were radiolabeled with 211At using both the linker PAB (N-succinimidyl-para-astatobenzoate) and a decaborate-based linker, and the biodistribution in tumor-bearing nude mice was investigated. The influence of L-lysine and Na-thiocyanate on the 211At uptake in normal tissues was also studied. Based on the biokinetic information obtained, the absorbed dose was calculated for different organs. Compared with a previous biodistribution with 125I, the 211At biodistribution using the PAB linker showed higher uptake in lungs, stomach, thyroid and salivary glands, indicating release of free 211At. When the decaborate-based linker was used, the uptake in those organs was decreased, but instead, high uptake in kidneys and liver was found. The uptake, when using the PAB linker, could be significantly reduced in some organs by the use of L-lysine and/or Na-thiocyanate. In conclusion, affibody molecules have suitable blood-kinetics for targeted radionuclide therapy with 211At. However, the labeling chemistry affects the distribution in normal organs to a high degree and needs to be improved to allow clinical use.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-104494 (URN)000245855800025 ()17390057 (PubMedID)
Available from: 2009-05-28 Created: 2009-05-28 Last updated: 2017-12-13Bibliographically approved
Babaei, M. H., Almqvist, Y., Orlova, A., Shafii, M., Kairemo, K. & Tolmachev, V. (2005). [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation. Oncology Reports, 13(6), 1169-75
Open this publication in new window or tab >>[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation
Show others...
2005 (English)In: Oncology Reports, ISSN 1021-335X, E-ISSN 1791-2431, Vol. 13, no 6, p. 1169-75Article in journal (Refereed) Published
Abstract [en]

Expression of epidermal growth factor receptors (EGFR) has prognostic and predictive value in many kinds of tumors. Imaging of expression of EGFR in vivo may give valuable diagnostic information. The epidermal growth factor (EGF), a natural ligand, is a possible candidate for the targeting of EGFR. The present study describes a method for preparation of (99m)Tc-EGF via the hydrazinopyridine-3-carboxylic acid (HYNIC) conjugation using tricine and ethylenediamine-N,N'-diacetic acid (EDDA) as co-ligands. Both conjugates bound EGFR expressing cells with nanomolar affinity, and demonstrated good intracellular retention. The complex with EDDA demonstrated much higher stability in blood serum and during cysteine challenge. Biodistribution of (99m)Tc-EDDA-HYNIC-EGF in normal mice demonstrated fast blood clearance of conjugate, and its ability to bind EGFR in vivo. (99m)Tc-EDDA-HYNIC-EGF is a promising candidate for visualization of EGFR expression in vivo.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-72815 (URN)15870939 (PubMedID)
Available from: 2005-05-30 Created: 2005-05-30 Last updated: 2017-12-14Bibliographically approved
Organisations

Search in DiVA

Show all publications